A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and provide more effective options for managing the disease. Here are some key details about the study:
- The treatment involves a combination of different therapies, which may work together to enhance effectiveness.
- This study is unique because it looks at how these therapies can be tailored to individual patients, potentially leading to better results.
- Patients will be monitored closely to assess how well the treatment works and to identify any side effects.
- The study includes a diverse group of participants, which helps ensure that the findings are applicable to a wide range of patients.
- Researchers are particularly interested in how this combination therapy can improve quality of life for patients.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
